Showing results (461-470 of 1,991) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|March 29, 2025
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trialGottfried Schlaug, Christy Cassarly, Jody A Feld, et al.
The Lancet. Neurology|March 22, 2025
Advances in diagnosis, classification, and management of pain in Parkinson's diseaseMichele Tinazzi, Marialuisa Gandolfi, Carlo Alberto Artusi, et al.
The Lancet. Neurology|April 19, 2025
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trialCristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, et al.
The Lancet. Neurology|February 16, 2024
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disordersGiovanni B Frisoni, Cristina Festari, Federico Massa, et al.
The Lancet. Neurology|July 31, 2023
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation studyAhmed Abdelhak, Franziska Petermeier, Pascal Benkert, et al.
The Lancet. Neurology|April 17, 2024
MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association studyRebecca R Valentino, William J Scotton, Shanu F Roemer, et al.
The Lancet. Neurology|April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialRabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
The Lancet. Neurology|April 21, 2024
Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial
The Lancet. Neurology|April 27, 2026
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trialLotte Kjærsgaard, Jonas Wiedemann, Wolfgang Singer, et al.
The Lancet. Neurology|April 20, 2026
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trialKimberly Y Lin, Anna Bucha, Kara McSweeney, et al.
Pageof 200